Drug Profile
Ethinylestradiol/levonorgestrel continuous - Pfizer
Alternative Names: EE/Levo continuous - Pfizer; EE/LNG continuous - Pfizer; Levo/EE continuous - Pfizer; Levonorgestrel/ethinlyestradiol continuous - Pfizer; Librel®; LNG/EE continuous - Pfizer; LybrelLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Wyeth
- Developer Pfizer; Wyeth
- Class Alkylated estrogenic steroids; Contraceptives; Hormonal replacements; Norpregnanes; Norpregnatrienes; Small molecules
- Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Pregnancy
- Discontinued Premenstrual dysphoric disorder; Premenstrual syndrome
Most Recent Events
- 27 Jun 2019 Chemical structure information added
- 07 Jun 2011 Generic equivalent approved in USA for Contraception/Pregnancy (Prevention)
- 16 Oct 2009 Wyeth has been acquired by Pfizer